CASE STUDY 04

The document examines the pharmaceutical landscape in Southern Africa, highlighting how weak regulation, fragmented registration policies, and intellectual property constraints hinder access to essential medicines. It discusses efforts by SADC and NEPAD to harmonise regulatory standards to reduce costs and improve safety, while noting that national sovereignty concerns and the dominance of larger states like South Africa complicate these efforts. The analysis emphasizes the critical role of generic medicines and the influence of global trade agreements like TRIPS on regional health outcomes.

• Access to medicines in sub-Saharan Africa is hindered by small markets, inconsistent medicine registration policies across Southern Africa, and a shortage of quality control laboratories for testing generic medicines.
• The Trade Related Aspects of Intellectual Property Rights (TRIPS) agreement creates barriers to pharmaceutical movement; while 14 of 15 SADC countries are WTO members and 57% have modified legislation for TRIPS compliance, the agreement's patent protections can make medicines unaffordable.
• Regional efforts to harmonise medicine regulation, including initiatives by NEPAD and the SADC Medicine Regulatory Authority Forum, have struggled to achieve significant results due to a lack of local regulatory capacity in member states.
• Implementation of regional regulatory coordination faces several obstructions, including member states' reluctance to relinquish national sovereignty, fears that smaller states will be marginalised by stronger ones, and concerns over potential job losses at national regulatory authorities.
• South Africa holds a dominant position in the SADC pharmaceutical sector, hosting approximately 40% of the region's 101 manufacturers and serving as the only country in the region capable of producing generic drugs.
• South Africa possesses the region's most advanced regulatory framework and has implemented TRIPS flexibilities in its national regulations, which is believed to help generic producers negotiate affordable licenses even though these flexibilities have not been formally used.
• The pharmaceutical industry, distributors, and pharmacies lack a visible push for SADC policy harmonisation, potentially because the region's market is small compared to developed economies or because weak regulation allows these actors to set prices to their own advantage.

APA

South African Institute of International Affairs (n.d.). CASE STUDY 04. https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf

Chicago

South African Institute of International Affairs. CASE STUDY 04. n.d. https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf.

Wikipedia

{{cite report |author=South African Institute of International Affairs |title=CASE STUDY 04 |url=https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf |access-date=17 August 2026 |via=Climate Insights Directory}}

BibTeX

@techreport{southafricaninstituteofinternationalaffairsndcase, author = {{South African Institute of International Affairs}}, title = {{CASE STUDY 04}}, institution = {South African Institute of International Affairs}, url = {https://saiia.org.za/wp-content/uploads/2014/10/141125_EDIP_GIZreport_pg47-52_CS4.pdf}, urldate = {2026-08-17}, note = {Indexed by Climate Insights Directory} }